1. Home
  2. GMRE vs EOLS Comparison

GMRE vs EOLS Comparison

Compare GMRE & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GMRE
  • EOLS
  • Stock Information
  • Founded
  • GMRE 2011
  • EOLS 2012
  • Country
  • GMRE United States
  • EOLS United States
  • Employees
  • GMRE N/A
  • EOLS N/A
  • Industry
  • GMRE Real Estate Investment Trusts
  • EOLS Biotechnology: Pharmaceutical Preparations
  • Sector
  • GMRE Real Estate
  • EOLS Health Care
  • Exchange
  • GMRE Nasdaq
  • EOLS Nasdaq
  • Market Cap
  • GMRE 508.9M
  • EOLS 493.5M
  • IPO Year
  • GMRE N/A
  • EOLS 2018
  • Fundamental
  • Price
  • GMRE $7.66
  • EOLS $7.40
  • Analyst Decision
  • GMRE Buy
  • EOLS Strong Buy
  • Analyst Count
  • GMRE 3
  • EOLS 5
  • Target Price
  • GMRE $10.38
  • EOLS $21.25
  • AVG Volume (30 Days)
  • GMRE 691.1K
  • EOLS 913.1K
  • Earning Date
  • GMRE 11-05-2025
  • EOLS 11-05-2025
  • Dividend Yield
  • GMRE 7.85%
  • EOLS N/A
  • EPS Growth
  • GMRE N/A
  • EOLS N/A
  • EPS
  • GMRE 0.07
  • EOLS N/A
  • Revenue
  • GMRE $141,896,000.00
  • EOLS $277,941,000.00
  • Revenue This Year
  • GMRE $7.69
  • EOLS $14.01
  • Revenue Next Year
  • GMRE $4.04
  • EOLS $29.46
  • P/E Ratio
  • GMRE $113.85
  • EOLS N/A
  • Revenue Growth
  • GMRE 2.95
  • EOLS 17.15
  • 52 Week Low
  • GMRE $6.06
  • EOLS $5.71
  • 52 Week High
  • GMRE $10.46
  • EOLS $17.82
  • Technical
  • Relative Strength Index (RSI)
  • GMRE 65.26
  • EOLS 47.37
  • Support Level
  • GMRE $7.26
  • EOLS $7.23
  • Resistance Level
  • GMRE $7.73
  • EOLS $7.75
  • Average True Range (ATR)
  • GMRE 0.14
  • EOLS 0.29
  • MACD
  • GMRE 0.02
  • EOLS 0.07
  • Stochastic Oscillator
  • GMRE 84.95
  • EOLS 37.91

About GMRE Global Medical REIT Inc.

Global Medical REIT Inc is engaged predominantly in the acquisition of purpose-built healthcare facilities and the leasing of those facilities to physician groups and regional and national healthcare systems. The company's principal business objective is to provide attractive, risk-adjusted returns to its stockholders through a combination of reliable dividends and long-term capital appreciation. Its healthcare facilities are located in secondary markets and suburbs of primary markets and are typically leased to single-tenants under triple-net leases.

About EOLS Evolus Inc.

Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.

Share on Social Networks: